Skip to main content

RNAi CRO Cenix Bioscience Shuts Down

NEW YORK (GenomeWeb) – RNAi contract research firm Cenix Bioscience is shutting down, according to a statement on the company's website.

Cenix CEO and CSO Christopher Echeverri confirmed the situation, but declined to comment further.

The company was founded about 15 years ago to provide high-throughput target discovery and validation services for academic and industry partners, and also developed research products such as genome-wide siRNA libraries. The German company had also been exploring RNAi delivery technologies for in vivo applications, and in 2012 established a US subsidiary to help establish partnerships in North America.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.